Top 3 Undervalued Small Caps With Insider Buying To Watch

In This Article:

As global markets grapple with economic slowdown worries and the S&P 500 Index experiences its sharpest weekly decline in 18 months, small-cap stocks are not immune to these broader market sentiments. With fewer job openings signaling a weakening U.S. labor market and heightened investor nervousness, identifying undervalued opportunities becomes crucial. In such a volatile environment, stocks that exhibit strong fundamentals combined with insider buying can present compelling investment opportunities.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Bytes Technology Group

22.9x

5.2x

18.73%

★★★★★☆

Essentra

771.1x

1.5x

42.70%

★★★★★☆

Genus

160.2x

1.9x

2.21%

★★★★★☆

Delek US Holdings

NA

0.1x

22.88%

★★★★★☆

CVS Group

22.8x

1.3x

40.27%

★★★★☆☆

Primaris Real Estate Investment Trust

12.3x

3.3x

40.66%

★★★★☆☆

German American Bancorp

13.7x

4.6x

47.35%

★★★☆☆☆

MYR Group

31.5x

0.4x

47.17%

★★★☆☆☆

Studsvik

20.3x

1.2x

42.39%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Click here to see the full list of 172 stocks from our Undervalued Small Caps With Insider Buying screener.

We'll examine a selection from our screener results.

Tabcorp Holdings

Simply Wall St Value Rating: ★★★★★☆

Overview: Tabcorp Holdings operates in gaming services and wagering and media, with a market cap of approximately A$4.38 billion.

Operations: Tabcorp Holdings generates revenue primarily from Wagering and Media ($2.16 billion) and Gaming Services ($176.1 million). The company has seen fluctuations in its net income margin, with a notable drop to -57.63% as of September 2024. Operating expenses have remained significant, often surpassing $2 billion annually, impacting overall profitability despite consistently high gross profit margins of 100%.

PE: -0.7x

Tabcorp Holdings, a small-cap stock, has seen significant insider confidence with share purchases in the last quarter. Despite reporting a net loss of A$1.36 billion for the year ending June 30, 2024, compared to net income of A$66.5 million the previous year, earnings are forecasted to grow by 117.91% annually. The company’s recent dividend decrease to A$0.003 per share and its reliance on external borrowing highlight both challenges and potential for future growth in this sector.

ASX:TAH Share price vs Value as at Sep 2024
ASX:TAH Share price vs Value as at Sep 2024

Genus

Simply Wall St Value Rating: ★★★★★☆

Overview: Genus is a biotechnology company focused on animal genetics, with operations in bovine and porcine sectors, and has a market cap of £2.50 billion.